• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SpringFire Laboratory Network adds ReproSource to affiliate laboratories

SpringFire Laboratory Network adds ReproSource to affiliate laboratories

October 19, 2012
CenterWatch Staff

SpringFire Laboratory Network, a network of independent, esoteric, high complexity laboratories, has added ReproSource Fertility Diagnostics, a Boston-based clinical laboratory and research organization that provides solutions for fertility testing and education, to its network of affiliate laboratories, which provides specialized testing services to clinical trial sponsors and CROs.

The agreement adds ReproSource’s male and female fertility testing services—including reproductive immunology, endocrinology, andrology and genetics—to SpringFire’s offering. The ReproSource addition brings the total number of SpringFire affiliate laboratories to eight with more than 1,000 testing offerings.

ReproSource brings an extensive background in trials and research, including sperm DNA integrity testing and ovarian reserve and hormone testing. A recent ReproSource study of Antimullerian Hormone (AMH) testing for ovarian reserve assessment represents the largest AMH study to date, involving 17,120 patients. The company’s extensive involvement in ovarian reserve testing research led to the development of an ovarian assessment diagnostic test that is the most accurate assessment of egg supply available using a single blood specimen and is used internationally by fertility experts. ReproSource also developed an assay for identifying damage to sperm cells caused by oxidative stress.

“Expanding our work with clinical research, product development and clinical trials is a great step forward in our mission to advance the field of fertility diagnostics and reproductive medicine,” said Charles Jenkins, vice president of ReproSource. “We are very excited to be a part of the Springfield Laboratory Network. Previously, measuring the effects of new medical treatments on egg supply and semen quality has been difficult to assess quantitatively. We look forward to helping identify the most cost effective way to ensure new treatments do not have adverse effects on egg supply.”

As experts in fertility testing and research, Jenkins said ReproSource offers SpringFire and its customers an exclusive fertility focus and multiple disciplines under one roof along with a biobank of blood and semen, male and female fertility testing, robust data management and flexible reporting.

With a combined menu of more than 1,000 specialty tests, SpringFire offers sponsors and CROs expertise and testing services in numerous therapeutic areas, including anatomical pathology, molecular genetics and women’s health.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing